Name:	edit_CollaborationAgreementPercentageOutstandingSharesIssued
Namespace Prefix:	edit_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	instant

The potential liability for company's sale success payments.

No definition available.

Name:	edit_CompanySaleSuccessPaymentsUnderPatentRights
Namespace Prefix:	edit_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

Represents the contract termination notice term under the license agreement.

No definition available.

Name:	edit_LicenseAgreementContractTerminationTerm
Namespace Prefix:	edit_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

Represents the percentage of net revenue threshold for potential milestone payments to be made under the license agreement.

No definition available.

Name:	edit_LicenseAgreementPercentageThresholdForPotentialMilestonePayments
Namespace Prefix:	edit_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

Amount of market capitalization.

No definition available.

Name:	edit_MarketCapitalization
Namespace Prefix:	edit_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

Represents the market capitalization threshold under license agreement.

No definition available.

Name:	edit_MarketCapitalizationThreshold
Namespace Prefix:	edit_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

Represents the payment terms for notes payable.

No definition available.

Name:	edit_NotesPayablePaymentTerms
Namespace Prefix:	edit_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

The number of licensed products, in a research and clinical milestones.

No definition available.

Name:	edit_NumberOfLicensedProducts
Namespace Prefix:	edit_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

Represents upfront payment fees to collaborators under agreements.

No definition available.

Name:	edit_PaymentsForUpfrontFeesToCollaborators
Namespace Prefix:	edit_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

Represents the percentage of third party royalties that may be credited against the royalties due to counter party.

No definition available.

Name:	edit_PercentageOfRoyaltiesPaidCreditedTowardsRoyaltiesDue
Namespace Prefix:	edit_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

The aggregate potential liability for future clinical, regulatory and commercial milestone payments related to product approval.

No definition available.

Name:	edit_PotentialLiabilityForClinicalRegulatoryAndCommercialMilestonePayments
Namespace Prefix:	edit_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

The aggregate potential liability for future clinical and regulatory milestone payments related to product approval.

No definition available.

Name:	edit_PotentialLiabilityForProductApprovalClinicalAndRegulatoryMilestonePayments
Namespace Prefix:	edit_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

The potential liability for sales milestone payments.

No definition available.

Name:	edit_PotentialLiabilityForSalesMilestones
Namespace Prefix:	edit_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(16))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(16))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Name:	us-gaap_NotesPayable
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

Name:	us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.

No definition available.

Name:	us-gaap_StockIssuedDuringPeriodSharesIssuedForServices
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

Name:	srt_CounterpartyNameAxis=edit_GeneralHospitalCorporationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	us-gaap_TypeOfArrangementAxis=edit_LicensePatentRightsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	srt_CounterpartyNameAxis=edit_HarvardBroadMitMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	us-gaap_TypeOfArrangementAxis=edit_Cpf1LicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	us-gaap_TypeOfArrangementAxis=edit_Cpf1MarketCapSuccessPaymentsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	us-gaap_TypeOfArrangementAxis=edit_Cas9IILicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	us-gaap_TypeOfArrangementAxis=edit_Cpf1SuccessPaymentsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	srt_RangeAxis=srt_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	srt_ProductOrServiceAxis=edit_ProductForTreatmentOfRareDiseaseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	srt_StatementGeographicalAxis=edit_UnitedStatesEuropeAndJapanMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	srt_ProductOrServiceAxis=edit_ProductForTreatmentOfHumanDiseaseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	srt_StatementGeographicalAxis=edit_UnitedStatesAndOneOtherLocationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: